Amgen reports Phase 3 results and Amgen stock trades at EUR 371.13

{
  "signal_id": "e4b3e645-c9cb-124f-aa81-476d64c63c4c",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-10-01T10:51:32+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/amgen-reports-phase-3-results-and-amgen-stock-trades-at-eur-371-13/70209973",
    "title": "Amgen reports Phase 3 results and Amgen stock trades at EUR 371.13 - AD HOC NEWS",
    "excerpt": "Amgen Inc. (ISIN US0311621009) reported positive Phase 3 results for dazodalibep in systemic Sjogren's disease on September 22, 2026, while Amgen stock was trading at EUR 371.13 at Lang & Schwarz on October 1, 2026. The euro quote was minus 0.03 percent against the EUR 371.25 prior close, leaving the clinical update and the earnings base as the central reference points for the stock. According to Amgen in its September 22, 2026 release, the OASIZ 301 study showed a statistically significant and clinically meaningful improvement in systemic disease activity at week 48 for adults with moderate-to-severe Sjogren's disease. The result adds a late-stage autoimmune asset to Amgen's pipeline, but the commercial value depends on further clinical and regulatory milestones. The OASIZ 303 study is expected to complete in the fourth quarter of 2026, giving investors a defined next data point for the program. MarketBeat reported that Amgen generated USD 10.05 billion in revenue in the second quarter of 2026, up 9.50 percent from the same quarter a year earlier. Adjusted earnings per share came in at USD 6.29, compared with a USD 5.62 consensus estimate. The same report said Amgen maintained adjusted full-year 2026 earnings-per-share guidance of USD 22.30 to USD 23.50. The quarterly dividend was USD 2.52 per share, adding an income component while the pipeline supplies the growth debate...",
    "summary": "Amgen reported adjusted earnings per share of USD 6.29 for the second quarter of 2026, surpassing the consensus estimate of USD 5.62.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2671505_1920_1080.webp",
    "confidence": 0.8,
    "published_at": "2026-10-01T10:51:32Z",
    "article_sentence": "Adjusted earnings per share came in at USD 6.29, compared with a USD 5.62 consensus estimate."
  }
}

curl https://signals.autobound.ai/v1/signals/e4b3e645-c9cb-124f-aa81-476d64c63c4c \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"amgen.com","limit":20}'